Changes in Renal Function after Different Tandem Hematopoietic Stem-cell Transplantation Approaches in Patients with Multiple Myeloma

다국어 초록 (Multilingual Abstract)

This study was done to observe the alteration of the estimated glomerular filtration rate (eGFR) in multiple myeloma patients according to type of tandem hematopoietic stem cell transplantation (HSCT). Forty-one patients were enrolled in this study. Twenty patients underwent autologous HSCT (auto-HSCT) and 21 patients underwent allogeneic HSCT (allo-HSCT). The changes in eGFR after the two tandem HSCT modalities were different between the two groups, according to the donor of stem cells (P = 0.016). In the auto-HSCT group,the eGFR, recorded 12 months after secondary HSCT, was significantly decreased compared with the eGFR recorded before stem cell mobilization (P = 0.005). Although there was no significant difference, the trend showed that the eGFR after allo-HSCT decreased from the previous HSCT until a month after secondary HSCT. In addition, after 6 months of secondary HSCT, the eGFR recovered to the level recorded prior to the HSCT (P = 0.062).
This difference may be due to total body irradiation, a calcineurin inhibitor, or maintemance therapy. Changes in renal function would be monitored closely for these patients. The recovery of the eGFR would be a main focus for the patients treated with the total body irradiation or the calcineurin inhibitor, a progressive decline of the eGFR would be also crucial for the patients treated with maintenance therapy.

참고문헌 (Reference)

1 엄기성, "일차 자가조혈모세포이식을 받은 다발성골수종 환자에서 이차 이식의 성적을 향상시키는 데 있어서의 이식 전 질환상태의 중요성" 대한혈액학회 41 (41): 5-5, 2006

2 정선경, "다발성골수종 환자의 진단 및 치료효과 추적을 위한 혈청 유리형 경쇄 정량검사의 의의" 대한진단검사의학회 28 (28): 169-173, 2008

3 Berenguer M, "Treatment of chronic hepatitis C in hemodialysis patients" 48 : 1690-1699, 2008

4 Izzedine H, "Thalidomide for the nephrologist" 20 : 2011-2012, 2005

5 Jones SG, "Severe increase in creatinine with hypocalcemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions" 119 : 576-577, 2002

6 Tricot G, "Safety of autotransplants with highdose melphalan in renal failure: a pharmacokinetic and toxicity study" 2 : 947-952, 1996

7 Diel IJ, "Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review" 17 : 719-725, 2009

8 Nunes R, "Reversible acute renal failure following single administration of fludarabine" 33 : 671-, 2004

9 Borg M, "Renal toxicity after total body irradiation" 54 : 1165-1173, 2002

10 Knudsen LM, "Renal function in newly diagnosed multiple myeloma: a demographic study of 1353 patients" 53 : 207-212, 1994

11 Alexanian R, "Renal failure in multiple myeloma: pathogenesis and prognostic implications" 150 : 1693-1695, 1990

12 Dimopoulos MA, "Pathogenesis and treatment of renal failure in multiple myeloma" 22 : 1485-1493, 2008

13 Brukamp K, "Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease" 1 : 685-694, 2006

14 Morgan GJ, "National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial" 376 : 1989-1999, 2010

15 Harousseau JL, "Maintenance treatment in multiple myeloma" 19 (19): 54-55, 2008

16 Mihelic R, "Maintenance therapy in multiple myeloma" 21 : 1150-1157, 2007

17 National Kidney Foundation, "K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification" 39 (39): 1-266, 2002

18 Lokhorst H, "International Myeloma Working Group. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma" 28 : 4521-4530, 2010

19 Attal M, "InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma" 349 : 2495-2502, 2003

20 Nair B, "Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols" 145 : 134-137, 2009

21 Lee CK, "Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant" 33 : 823-828, 2004

22 Kahan BD, "Cyclosporine" 321 : 1725-1738, 1989

23 Chan GS, "Clinicopathologic analysis of renal biopsies after haematopoietic stem cell transplantation" 13 : 322-330, 2008

24 Hingorani S, "Chronic kidney disease in long-term survivors of hematopoietic cell transplantation: epidemiology, pathogenesis, and treatment" 17 : 1995-2005, 2006

25 Parikh GC, "Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma" 15 : 812-816, 2009

26 Parikh CR, "Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant" 67 : 1999-2005, 2005

27 Levey AS, "A simplified equation to predict glomerular filtration rate from serum creatinine" 11 : 155-, 2000

28 Bruno B, "A comparison of allografting with autografting for newly diagnosed myeloma" 356 : 1110-1120, 2007

29 Durie BG, "A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival" 36 : 842-854, 1975